Fig. 3: Relative abundance of select pre-treatment bile acids predicts peanut oral immunotherapy outcomes.
From: Gut microbial bile and amino acid metabolism associate with peanut oral immunotherapy failure
a Factor 2 from MOFA2 analyses is the most significant differential factor between POIT response groups and weighted significantly higher in no remission groups compared to D+R+ group (D+R+ vs. D+R−, P = 0.0028; D+R+ vs. D−R−, P = 0.00045, two-sided Wilcoxon signed-rank test) (D+R+, n = 28, D+R−, n = 69, and D−R−, n = 18). Data are presented as mean values ± SEM. Boxplots show the median (center line), 25th and 75th percentiles (box bounds), and whiskers extend to values within 1.5× the interquartile range. b Top 5 microbial pathways contributing to the Factor 2 weight contain gluconeogenesis and anaerobic energy metabolism pathways. c Top 5 metabolites contributing to the Factor 2 weight are BA metabolites including 7-ketolithocholate and 7-ketodeoxycholate (D+R+, n = 28, D+R−, n = 69, and D−R−, n = 18). d The predictive ability of the logistic regression model is expressed as the Area Under Curve (AUC) which is computed from 100 times repeated five-fold cross-validation. Blue line shows the average across the 100 times repeated five-fold cross-validations with the shaded area representing the 95% CI (mean AUC ± standard deviation). The dashed diagonal line represents random chance. e The copy number of EC. 1.1.1.201 positively correlates with 7-ketodeoxycholate (n = 121, r = 0.22, p = 0.013. Adjusted for age), and f 7-ketolithocholate (n = 121, r = 0.25, p = 0.005, Adjusted for age). Two-sided Pearson correlation. The shaded area around the line represents the 95% confidence interval for the fitted regression line. Source data are provided as a Source Data file.
